Harbour BioMed will partner with Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize its Phase II cancer immunotherapy candidate A167 worldwide except greater China, through an exclusive collaboration that could generate more than $350 million for Kelun-Biotech, the companies said today. A167 (formerly KL-A167) is an anti-programmed death-ligand 1 (PD-L1) antibody currently in multiple Phase I and Phase II trials in China targeting lymphoma and solid tumors. A167 is designed to bind to immune checkpoint protein PD-L1, and reactivate T cells in the body against cancer cells. The antibody is envisioned for use in a broad range of solid tumor and hematological malignancies. Among them is relapsed or refractory classical Hodgkin lymphoma, in which Kelun-Biotech plans to recruit an estimated 104 participants for an open, multicenter Phase II trial ( NCT03580564 ), with the efficacy of A167 to be measured by Overall Response Rate (ORR). The study’s ...